Graves’ Ophthalmopathy (Ophthalmology) – Drugs in Development, 2021

Global Markets Direct’s, ‘Graves' Ophthalmopathy – Drugs In Development, 2021’, provides an overview of the Graves' Ophthalmopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy

– The report reviews pipeline therapeutics for Graves' Ophthalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Graves' Ophthalmopathy therapeutics and enlists all their major and minor projects

– The report assesses Graves' Ophthalmopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Graves' Ophthalmopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Graves' Ophthalmopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

advanceCor GmbH

Enceladus Pharmaceuticals BV

Genmab AS

GlaxoSmithKline Plc

HanAll Biopharma Co Ltd

ImmunoGen Inc

Novartis AG

Pierre Fabre Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Viridian Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Graves' Ophthalmopathy - Overview

Graves' Ophthalmopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Graves' Ophthalmopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Graves' Ophthalmopathy - Companies Involved in Therapeutics Development

Graves' Ophthalmopathy - Drug Profiles

Graves' Ophthalmopathy - Dormant Projects

Graves' Ophthalmopathy - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Graves' Ophthalmopathy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Graves' Ophthalmopathy – Pipeline by advanceCor GmbH, 2021

Graves' Ophthalmopathy – Pipeline by Enceladus Pharmaceuticals BV, 2021

Graves' Ophthalmopathy – Pipeline by Genmab AS, 2021

Graves' Ophthalmopathy – Pipeline by GlaxoSmithKline Plc, 2021

Graves' Ophthalmopathy – Pipeline by HanAll Biopharma Co Ltd, 2021

Graves' Ophthalmopathy – Pipeline by ImmunoGen Inc, 2021

Graves' Ophthalmopathy – Pipeline by Novartis AG, 2021

Graves' Ophthalmopathy – Pipeline by Pierre Fabre Pharmaceuticals Inc, 2021

Graves' Ophthalmopathy – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Graves' Ophthalmopathy – Pipeline by Viridian Therapeutics Inc, 2021

Graves' Ophthalmopathy – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Graves' Ophthalmopathy, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports